MP0250, a VEGF and HGF neutralizing DARPin^® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models.

ABSTRACT:

Background

The VEGF/VEGFR and the HGF/cMET pathways are key mediators of the interplay of tumor cells and their microenvironment. However, inhibition of VEGF has been shown to produce only limited clinical benefit and inhibition of the activation of cMET by HGF has not translated into clinical benefit in pivotal trials. MP0250, a DARPin^® molecule that specifically inhibits both VEGF and HGF has been developed to explore the clinical potential of dual inhibition of these pathways.

Results

MP0250 binding to VEGF and HGF inhibited downstream signalling through VEGFR2 and cMET resulting in inhibition of proliferation of VEGF- and HGF-dependent cells. Antitumor activity was demonstrated in VEGF- and HGF-dependent xenograft and syngeneic models with activity superior to

SUBMITTER: Fiedler U 

PROVIDER: S-EPMC5716736 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature